Publications by authors named "D Cernea"
Background: Craniospinal irradiation (CSI) is a complex radiotherapy (RT) technique required for treating specific brain tumors and some hematologic malignancies. With large volumes of hematogenous bone marrow (BM) being irradiated, CSI could cause acute hematologic toxicity, leading to treatment interruptions or severe complications. We report on the dynamics and dose/volume predictors of hematologic toxicity during CSI.
View Article and Find Full Text PDFArticle Synopsis
- This study evaluates a deep-learning, MRI-based auto-contouring tool aimed at improving the speed and accuracy of delineating brain organs at risk during radiotherapy, compared to manual methods.
- The research involved analyzing data from thirty patients, where both AI-generated contours and manually corrected contours were compared using various accuracy metrics like Dice Similarity Coefficient and mean surface distance.
- Results indicated that auto-contouring was significantly faster than manual contouring, with good accuracy for larger structures; however, improvements are needed for smaller structures to enhance overall effectiveness in clinical practice.
Tomotherapy is a method of delivering rotational IMRT offering various advantages, notably for complex and large targets such as the cranio-spinal axis. This systematic literature review reports on main clinical outcomes and toxicities in patients with various cancer types that received whole craniospinal axis irradiation (CSI) using Tomotherapy and offers a comprehensive comparison between Tomotherapy and other radiotherapy delivery techniques. Databases including PubMed, PubMed Central, Embase, and Cochrane were searched using the keywords "tomotherapy" AND "craniospinal".
View Article and Find Full Text PDFEpidemiology of Traumatic Brain Injury in Oltenia Region: a Retrospective Study.
Curr Health Sci J
March 2018
Traumatic brain injury (TBI) represents a common cause of presentation in the emergency room and is considered a major health problem all over the world. Our study objective was to provide a regional perspective from a county hospital regarding epidemiologic aspect of TBI in a single year and to compare it with existing studies. 592 patients fulfilled the inclusions criteria and their characteristics were noted.
View Article and Find Full Text PDFArticle Synopsis
- A study evaluated the effectiveness and safety of bevacizumab (BEV) for patients with recurrent glioblastoma who had already undergone first-line treatment with radiotherapy and temozolomide.
- The TAMIGA trial involved randomizing patients after they experienced disease progression into two groups: one receiving lomustine (CCNU) with BEV and the other receiving CCNU with a placebo.
- Results indicated that the trial was halted due to high dropout rates, with median survival slightly better in the CCNU + BEV group (6.4 months) compared to the CCNU + placebo group (5.5 months), but the difference was not statistically significant.